Wechselwirkungen · Erleada
Erleada 240 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-139415 · Präparat HOS-098330
In humans, apalutamide is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9. In a drug-drug interaction study using a cocktail approach, co-administration of apalutamide with single oral doses of sensitive CYP substrates resulted in a 92% decrease in the AUC of midazolam (CYP3A4 substrate), 85% decrease in the AUC of omeprazole (CYP2C19 substrate), and 46% decrease in the AUC of S-warfarin (CYP2C9 substrate). Apalutamide did not cause clinically meaningful changes in exposure to the CYP2C8 substrate. Concomitant use of Erleada with medicinal products that are primarily metabolised by CYP3A4 (e.g., darunavir, felodipine, midazolam, simvastatin), CYP2C19 (e.g., diazepam, omeprazole), or CYP2C9 (e.g., warfarin, phenytoin) can result in lower exposure to these medicinal products. Substitution for these medicinal products is recommended when possible or evaluation for loss of efficacy should be performed if the medicinal product is continued. If given with warfarin, INR should be monitored during Erleada treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): felodipine (HOS-108908) simvastatin (HOS-086158) diazepam (HOS-085904) darunavir (HOS-086181) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-22T12:55:00Z · SHA-256 0e855910bdce0fdee217ba5d06d9b56e25e15ba99cd5eb9f6069185d820c69fe · Passage 410b30a35653d98d4feef0196846c1493b3bdef3294a8f6be71507634190423b · Zeichen 4005–5049 im Abschnitt